REFERENCES
- Larson S., Schall G., DiChiro G. The influence of previous lumbar puncture and pneumoencephalography on the incidence of unsuccessful radioisotope cisternography. J. Nuclear Med 1971; 12: 555–557, [CSA]
- Blaney S. M., Poplack D. G. Pharmacologic strategies for the treatment of meningeal malignancy. Invest. New Drugs 1996; 14: 69–85, [INFOTRIEVE], [CSA], [CROSSREF]
- Bleyer W. A., Poplack D. G., Simon R. M. “Concentration x time” methotrexate via a subcutaneous reservoir: a less toxic regimen for intraventricular chemotherapy of central nervous system neoplasms. Blood 1978; 51(5)835–842, [INFOTRIEVE], [CSA]
- Moser A. M., Adamson P. C., Gillespie A. J., Poplack D. G., Balis F. M. Intraventricular concentration times time (C × T) methotrexate and cytarabine for patients with recurrent meningeal leukemia and lymphoma. Cancer 1999; 85(2)511–516, [INFOTRIEVE], [CSA], [CROSSREF]
- Blasberg R., Patlak C., Fernstermacher J. Intrathecal chemotherapy. Brain tissue profiles after ventriculo-cisternal perfusion. J. Pharm. Exp. Therap. 1975; 195: 73–83, [CSA]
- Blaney S. M., Cole D. E., Balis F. M., Godwin K., Poplack D. G. Plasma and cerebrospinal fluid pharmacokinetic study of topotecan in nonhuman primates. Cancer Res 1993; 53(4)725–727, [INFOTRIEVE], [CSA]
- Blaney S. M., Cole D. E., Godwin K., Sung C., Poplack D. G., Balis F M. Intrathecal administration of topotecan in nonhuman primates. Cancer Chemother Pharmacol 1995; 36(2)121–124, [INFOTRIEVE], [CSA]
- Blaney S. M., Heideman R., Berg S., et al. Phase I clinical trial of intrathecal topotecan in patients with neoplastic meningitis. J. Clin. Oncol. 2003; 21(1)143–147, [INFOTRIEVE], [CSA], [CROSSREF]
- Houghton P. J., Cheshire P. J., Mailman J. D., 2nd, et al. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol 1995; 36(5)393–403, [INFOTRIEVE], [CSA]
- Blaney S. M., Balis F. M., Berg S., et al. Intrathecal mafosfamide: a preclinical pharmacology and phase I trial. J. Clin. Oncol. 2005; 23(7)1555–1563, [INFOTRIEVE], [CSA], [CROSSREF]
- Blaney S. M., Boyett J., Friedman H., et al. Phase I clinical trial of mafosfamide in infants and children aged 3 years or younger with newly diagnosed embryonal tumors: a pediatric brain tumor consortium study (PBTC-001). J. Clin. Oncol. 2005; 23(3)525–531, [INFOTRIEVE], [CSA], [CROSSREF]
- Slave I., Schuller E., Czech T., Hainfellner J. A., Seidl R., Dieckmann K. Intrathecal mafosfamide therapy for pediatric brain tumors with meningeal dissemination. J. Neurooncol. 1998; 38(2–3)213–218, [CSA], [CROSSREF]
- Heideman R., Packer R., Albright L. Tumors of the central nervous system. Lippincott-Raven, Philadelphia, PA 1997
- Chabner B. The role of drugs in cancer treatment. WB Saunders Co, Philadelphia 1982; 3–14
- Zimm S., Collins J. M., Miser J., Chatterji D., Poplack D. G. Cytosine arabinoside cerebrospinal fluid kinetics. Clin. Pharmacol. Ther. 1984; 35(6)826–830, [INFOTRIEVE], [CSA]
- Murry D. J., Blaney S. M. Clinical pharmacology of encapsulated sustained-release cytarabine. Ann. Pharmacother 2000; 34(10)1173–1178, [INFOTRIEVE], [CSA], [CROSSREF]
- Kim S., Chatelut E., Kim J., et al. Extended CSF cytarabine exposure following intrathecal administration of DTC 101. J Clin Oncol 1993; 11: 2186–2193, [INFOTRIEVE], [CSA]
- Bomgaars L., Geyer J. R., Franklin J., et al. Phase I trial of intrathecal liposomal cytarabine in children with neoplastic meningitis. J. Clin. Oncol. 2004; 22(19)3916–3921, [INFOTRIEVE], [CSA], [CROSSREF]
- Chamberlain M. C., Khatibi S., Kim J. C., Howell S. B., Chatelut E., Kim S. Treatment of leptomeningeal metastasis with intraventricular administration of depot cytarabine (DTC 101). A phase I study. Arch. Neurol. 1993; 50(3)261–264, [INFOTRIEVE], [CSA]
- Storniolo A. M., Enas N. H., Brown C. A., Voi M., Rothenberg M. L., Schilsky R. An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma. Cancer 1999; 85(6)1261–1268, [INFOTRIEVE], [CSA], [CROSSREF]
- Ozols R. F. The current role of gemcitabine in ovarian cancer. Semin Oncol 2001; 28(2Suppl7)18–24, [INFOTRIEVE], [CSA], [CROSSREF]
- von Minckwitz G., Bauknecht T., Visseren-Grul C. M., Neijt J. P. Phase II study of gemcitabine in ovarian cancer. Ann. Oncol. 1999; 10(7)853–855, [INFOTRIEVE], [CSA], [CROSSREF]
- Catimel G., Vermorken J. B., Clavel M., et al. A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann Oncol 1994; 5(6)543–547, [INFOTRIEVE], [CSA]
- Vogelzang N. J., Stadler W. M. Gemcitabine and other new chemotherapeutic agents for the treatment of metastatic bladder cancer. Urology 1999; 53(2)243–250, [INFOTRIEVE], [CSA], [CROSSREF]
- Luftner D., Flath B., Akrivakis C., Grunewald R., Mergenthaler H. G., Possinger K. Gemcitabine for palliative treatment in metastatic breast cancer. J Cancer Res Clin Oncol 1998; 124(10)527–531, [INFOTRIEVE], [CSA], [CROSSREF]
- Postmus P. E., Schramel F. M., Smit E. F. Evaluation of new drugs in small cell lung cancer: the activity of gemcitabine. Semin Oncol. 1998; 25(4 Suppl 9)79–82, [INFOTRIEVE], [CSA]
- Savage D. G., Rule S. A., Tighe M., et al. Gemcitabine for relapsed or resistant lymphoma. Ann Oncol 2000; 11(5)595–597, [INFOTRIEVE], [CSA], [CROSSREF]
- Fossa A., Santoro A., Hiddemann W., et al. Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma. J. Clin. Oncol. 1999; 17(12)3786–3792, [INFOTRIEVE], [CSA]
- Kerr J. Z., Berg S. L., Dauser R., et al. Plasma and cerebrospinal fluid pharmacokinetics of gemcitabine after intravenous administration in nonhuman primates. Cancer Chemother Pharmacol 2001; 47(5)411–414, [INFOTRIEVE], [CSA], [CROSSREF]
- Egorin M. J., Zuhowski E. G., McCully C. M., et al. Pharmacokinetics of intrathecal gemcitabine in nonhuman primates. Clin. Cancer Res. 2002; 8(7)2437–2442, [INFOTRIEVE], [CSA]
- Aaron R. H., Elion G. B., Colvin O. M., et al. Busulfan therapy of central nervous system xenografts in athymic mice. Cancer Chemother Pharmacol 1994; 35(2)127–131, [INFOTRIEVE], [CSA]
- Archer G. E., Sampson J. H., McLendon R. E., et al. Intrathecal busulfan treatment of human neoplastic meningitis in athymic nude rats. J. Neurooncol. 1999; 44(3)233–241, [INFOTRIEVE], [CSA], [CROSSREF]
- Quinn J. A., Glantz M., Petros W., et al. Phase I trial of intrathecal Spartaject busulfan for patients with neoplastic meningitis. Proc. Am. Soc. Clin. Oncol. 2002; 21, abstr 318[CSA]
- Gururangan S., Friedman H. S., Phillips P. C., et al. Phase I study of intrathecal (i.t) Spartaject busulfan (Bu) in children with neoplastic meningitis (NM): A Pediatric Brain Tumor Consortium Trial. Proc. Am. Soc. Clin. Oncol. 2003; 22(114), (abstr 456)[CSA]
- van Maanen J. M., Retel J., de Vries J., Pinedo H. M. Mechanism of action of antitumor drug etoposide: a review. J. Natl. Cancer. Inst. 1988; 80(19)1526–1533, [INFOTRIEVE], [CSA]
- Fleischhack G., Reif S., Hasan C., Jaehde U., Hettmer S., Bode U. Feasibility of intraventricular administration of etoposide in patients with metastatic brain tumours. Br. J. Cancer 2001; 84(11)1453–1459, [INFOTRIEVE], [CSA], [CROSSREF]
- Slave I., Schuller E., Falger J., et al. Feasibility of long-term intraventricular therapy with mafosfamide (n = 26) and etoposide (n = 11): experience in 26 children with disseminated malignant brain tumors. J. Neurooncol. 2003; 64(3)239–247, [CSA], [CROSSREF]
- Herrlinger U., Weller M., Schaber M. New aspects of immunotherapy of leptomeningeal metastasis. J. Neuro-Oncol. 1998; 38: 233–239, [CSA], [CROSSREF]
- Moser R., Bruner J., Grimm E. Biologic therapy for brain tumors. Cancer Bull. 1991; 43(2)117–124, [CSA]
- Silvani A., Salmaggi A., Parmiaini G., Boiardi A. Successful adoptive immunotherapy with lymphokine-activated killer cells in the treatment of medulloblastoma diesseminated via cerebrospinal fluid: case rerport. Neurosurg. 1994; 34: 1078–1081, [CSA]
- Chamberlain M. C. A phase II trial of intra-cerebrospinal fluid alpha interferon in the treatment of neoplastic meningitis. Cancer 2002; 94(10)2675–2680, [INFOTRIEVE], [CSA], [CROSSREF]
- Miederer M., McDevitt M. R., Borchardt P., et al. Treatment of neuroblastoma meningeal carcinomatosis with intrathecal application of alpha-emitting atomic nanogenerators targeting disialo-ganglioside GD2. Clin. Cancer Res. 2004; 10(20)6985–6992, [INFOTRIEVE], [CSA], [CROSSREF]
- Kramer K., Cheung N. K., Humm J. L., et al. Targeted radioimmunotherapy for leptomeningeal cancer using (131)I-3F8. Med. Pediatr. Oncol. 2000; 35(6)716–718, [INFOTRIEVE], [CSA], [CROSSREF]
- Bergman I., Barmada M. A., Heller G., Griffin J. A., Cheung N. K. Treatment of neoplastic meningeal xenografts by intraventricular administration of an antiganglioside monoclonal antibody, 3F8. Int J Cancer 1999; 82(4)538–548, [INFOTRIEVE], [CSA], [CROSSREF]
- Bergman I., Pohl C. R., Venkataramanan R., et al. Intrathecal administration of an anti-ganglioside antibody results in specific accumulation within meningeal neoplastic xenografts in nude rats. J. Immunother. 1999; 22(2)114–123, [INFOTRIEVE], [CSA]
- Kramer K., Cheung N. K., Humm J. L., et al. Intrathecal 13-I-labeled 3F8 antibody in patients with GD2-expressing central nervous system and leptomeningeal neoplasms. Neuro-Oncology 2004; 5(4)429, (abstr Exp 412)[CSA]
- Brown M. T., Coleman R. E., Friedman A. H., et al. Intrathecal 1311-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial results. Clin Cancer Res 1996; 2(6)963–972, [INFOTRIEVE], [CSA]
- Schulz H., Pels H., Schmidt-Wolf I., Zeelen U., Germing U., Engert A. Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibody rituximab. Haematologica 2004; 89(6)753–754, [INFOTRIEVE], [CSA]
- Schulz H., Pels H., Schlegel U., Zeelen U., Germing U., Engert A. Intraventricular application of rituximab as a treatment option in patients with CNS lymphoma and leptomeningeal disease. Proc. Am. Soc. Clin. Oncol. 2004; 23: 112, (abstr 1521)[CSA]
- Pels H., Schulz H., Schlegel U., Engert A. Treatment of CNS lymphoma with the anti-CD20 antibody rituximab: experience with two cases and review of the literature. Onkologie 2003; 26(4)351–354, [INFOTRIEVE], [CSA], [CROSSREF]
- Rubenstein J. L., Shen A., Abrey L., et al. Results from a phase I study of Intraventricular administration of rituximab in patients with recurrent lymphomatous meningitis. Proc. Am. Soc. Clin. Oncol. 2004; 23: 578, abstr 6593[CSA]